By accepting you will be accessing a service provided by a third-party external to

MS Therapies Among Limited Offerings Through AllianceRx Walgreens Prime

August 16, 2019

MS Therapies Among Limited Offerings Through AllianceRx Walgreens Prime

Medications for treating certain rare and chronic conditions,  including Multiple Sclerosis (MS), are now available from the specialty and home delivery pharmacy AllianceRx Walgreens Prime, the company announced.
The newly included specialty medications are all limited distribution drugs (LDDs), which means the drug manufacturers have signed agreements giving very few (or even just one) distributors the right to sell their products.
The newly included LDDs for MS treatment are Mayzent (siponimod) and Mavenclad (cladribine). Both of these therapies work by reducing the activity of the immune system with the goal of minimizing immune cell-mediated damage to neurons that is the defining feature of MS.
#Mayzent was approved by the U.S. Food and Drug Administration (FDA) in March for the treatment of relapsing forms of MS, including relapsing-remitting MS (RRMS), clinically isolated syndrome (CIS), and active secondary progressive MS (SPMS). Mayzent is manufactured by Novartis.
#Mavenclad, manufactured by EMD Serono (known as Merck KGaA outside the U.S. and Canada), was approved by the FDA (also in March) for RRMS and active SPMS. Because of its safety profile, Mavenclad is recommended only for MS patients who already have tried other MS therapies, but who did not have an adequate response and/or were not able to tolerate those treatments. Of note, the prescribing information for Mavenclad includes a warning that it may increase the risk of cancer, or cause harm to a developing fetus.

This Article is Provided by:  #MSViewsandNews
Visit our MS Learning Channel on YouTube:
Original author: Stuart
Dark Rimmed Brain Lesions May Be Signal of Aggress...
The Importance of Stretching With Multiple Scleros...


No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Wednesday, 27 May 2020

Captcha Image RSS Statement

Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.